About Alexion Pharmaceuticals, Inc
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts. Address: 121 Seaport Boulevard, Boston, MA, United States, 02210
Alexion Pharmaceuticals, Inc News and around…
Latest news about Alexion Pharmaceuticals, Inc (ALXN) common stock and company :
It's not likely.
The new approval to treat a form of lung cancer will be pivotal to dominating a massive market.
AstraZeneca stock returned to an uptrend after the company finished its Alexion buyout. Is AZN stock a buy or a sell right now?
Alexion (ALXN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ALXN vs. TECH: Which Stock Is the Better Value Option?
Ultomiris, the successor toAlexion Pharmaceuticals Inc's(NASDAQ: ALXN) paroxysmal nocturnal hemoglobinuria (PNH) drug ...
With UK approval, the $39 billion deal for rare disorders biotech company Alexion Pharmaceuticals is set to close on July 21.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips What did the stock market do today? It saw Moderna reach a major index, it saw Americans spending big, and it saw Biden targeting China. The post What Did the Stock Market Do Today? 3 Big Stories to Catch Up On. appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now It doesn’t matter if you have $500 in savings or $5 million. Do this now.
Moderna, Inc (NASDAQ: MRNA) gapped up 6.64% Friday morning after it was announced the company will join theS&P ...
Alexion (ALXN) announces that the phase III study of Ultomiris for the indication of gMG met its primary goal.
Find out why a big index move is so interesting for investors.
Moderna stock is set to join the benchmark on July 21, replacing Alexion Pharmaceuticals.
The company joins the S&P 500 index next week.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Moderna (MRNA) stock is on the rise Friday as the company prepares to join the S&P 500 next week replacing Alexion Pharmaceuticals (ALXN). The post MRNA Stock: 10 Things to Know About Moderna as It Gets Ready to Join the S&P 500 appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now It doesn’t matter if you have $500 in savings or $5 million. Do this now.
Alexion Pharmaceuticals Inc(NASDAQ: ALXN)announced topline resultsfrom a Phase 3 study evaluating Ultomiris ...
U.S. stock-index futures on Friday were trading slightly higher ahead of a data on June retail sales, after a week featuring assurances by Federal Reserve Chairman Jerome Powell that surging inflation was a temporary phenomenon.
Shares of COVID-19 vaccine company Moderna, Inc. (NASDAQ: MRNA), which ended Thursday's session with a market cap of $104.3 billion ...
By Dhirendra Tripathi
Moderna Inc. (NASD:MRNA) will replace Alexion Pharmaceuticals Inc. (NASD:ALXN) in the S&P 500 effective prior to the opening of trading on Wednesday, July 21. AstraZeneca Plc (LSE:AZN; NASD:AZN) is acquiring Alexion Pharmaceuticals in a deal expected to be completed soon pending final closing conditions.
Moderna Inc., a biotechnology company catapulted to notoriety after it produced a highly effective COVID-19 vaccine, is set to join the S&P 500 index, a seal of approval that will put the stock in countless index-tracking and actively managed funds and retirement accounts.
Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG).
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...
Alexion (ALXN) could produce exceptional returns because of its solid growth attributes.
Before 10 a.m. ET Wednesday, 81 stocks made new 52-week highs. Areas of Interest: Apple (NASDAQ:AAPL) was ...
AstraZeneca (AZN) obtains UK Competition and Markets Authority's permission for the impending acquisition of Alexion. The deal is expected to close on Jul 21, 2021.